Vigil Neuroscience is a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Co.'s key candidate, VGL101, is a fully human monoclonal antibody that is designed to activate Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Co. is also developing a small molecule TREM2 agonist for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. The initial focus of Co.'s small molecule TREM2 agonist program is for the treatment of Alzheimer's disease. The VIGL average annual return since 2022 is shown above.
The Average Annual Return on the VIGL average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VIGL average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VIGL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|